AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - results of two parallel first-in-human phase I studies.
Omlin A, Jones RJ, van der Noll R, Satoh T, Niwakawa M, Smith SA, Graham J, Ong M, Finkelman RD, Schellens JH, Zivi A, Crespo M, Riisnaes R, Nava-Rodrigues D, Malone MD, Dive C, Sloane R, Moore D, Alumkal JJ, Dymond A, Dickinson PA, Ranson M, Clack G, de Bono J, Elliott T.
Omlin A, et al. Among authors: finkelman rd.
Invest New Drugs. 2015 Jun;33(3):679-90. doi: 10.1007/s10637-015-0235-5. Epub 2015 Apr 30.
Invest New Drugs. 2015.
PMID: 25920479
Clinical Trial.